# A Phase1 Study of VIB9600

> **NCT03621605** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 24 (actual)

## Conditions studied

- Safety Issues

## Interventions

- **BIOLOGICAL:** VIB9600
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03621605
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-14
- **Primary completion:** 2019-04-08
- **Final completion:** 2019-04-08
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Study terminated due to tolerability issues.
- **Last updated:** 2024-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03621605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03621605, "A Phase1 Study of VIB9600". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03621605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*